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Inherent problems with randomized clinical trials
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Clifford J. Buckley, MD, Robert B. Rutherford, MD, Edward B. Diethrich, MD, and
Shirley D. Buckley, MSN, RN, CS, Temple, Tex
Randomized clinical trials (RCTs) offering an observation/no treatment (OBS/NoRx) arm as control and which are
focused on the management of a condition with potentially life-threatening consequences, however small the risk, often
experience a significant rate of crossover to treatment by those randomized to the OBS/NoRx arm. Results of these trials
when analyzed on intent-to-treat basis often fail to resolve the issue at which they were directed. The authors have
observed this in trials of abdominal aortic aneurysms with this design and use these to exemplify the dilemmas RCTs of
such design create, with crossovers ranging from 27% to over 60% ( EVAR II, UKSAT, ADAM, PIVOTAL). Results of
these trials are frequently used as level I medical evidence and their potential impact on clinical decision making and
reimbursement can be quite significant and long-lasting. Recommendations regarding trial end points and suggestions to
mitigate the high crossover effect are offered. It may be that some clinical conditions dealing with potentially
life-threatening problems should not be studied in randomized prospective clinical trials containing an OBS/NoRx arm.
(J Vasc Surg 2010;52:237-41.)Prospective randomized clinical trials (RCTs) are gen-
erally considered a “gold standard” and are offered as level
I medical evidence. By design, some RCTs have investiga-
tional arms offering observation or no treatment (OBS/
NoRx). Unlike drug trials, RCTs investigating a device or
procedure cannot utilize placebos and randomization to
OBS/NoRx is transparent to the patient subject. Our
experience in enrolling patients in RCTs with this design
reflects an inherent problem with such RCTs in that a
significant number of patients who initially accept random-
ization to OBS/NoRx ultimately cross over to a treatment
arm. This is particularly true when the RCT is focused on a
clinical condition that may be perceived by the patient, or
family and friends, as life-threatening, such as abdominal
aortic aneurysms (AAAs). The frequency with which pa-
tients cross over may either confound the outcomes of
these trials and/or undermine the acceptance of conclu-
sions based on an intent-to-treat analysis, which should not
be used in this situation. Intent-to-treat data analytic strat-
egy was developed for drug trials in which some patients
dropped out (after 10-12 weeks) before receiving full treat-
ment. To determine whether the full treatment worked,
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doi:10.1016/j.jvs.2010.02.255you could just use the subjects who completed treatment
when analyzing outcome data for these studies. Our expe-
riences with patients enrolled in a current AAA RCT exem-
plify this, but the extent of this problem is also apparent
from reviewing other AAA RCTs with OBS/NoRx arms.
These observations will be used to characterize the nature
and extent of this problem.
OBSERVATIONS
We recently enrolled 37 patients into a “small” AAA
(4- to 5-cm-diameter) RCT in which endovascular aneurysm
repair (EVAR) is being compared with an OBS/NoRx arm
featuring periodic ultrasound surveillance (US/S). During
the first 36 months of the study, over 50% of subjects (10 of
the 19) we enrolled in the OBS/NoRx arm crossed over to
treatment. Although the reasons given for crossing over
seemed insignificant to us, they clearly reflected the pa-
tients’ growing concerns over not being treated for a con-
dition, which, they felt, or had come to feel, deserved
treatment. The reasons for requesting crossover were typi-
cally related by the patient as abdominal pain and/or
tenderness but were frequently associated with comments
made by relatives or friends or information gleaned from
the Internet. This particular RCT’s protocol recognized
four acceptable reasons for crossing over from periodic
US/S to EVAR: (1) AAA diameter reaching the threshold
chosen for intervention; (2) a rate of increase in AAA
diameter exceeding protocol interval growth limits; (3) the
patient’s AAA becoming symptomatic; and (4) patient
requesting treatment. The last two reasons were invoked in
8 of 10 of our patients’ crossing over from the observational
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evolved into a familiar pattern, as related below.
As part of the informed consent, patients were coun-
seled at the outset to report any and all discomfort or pain
related to the back, abdomen, or groin. This was under-
standably required because of the possibility of AAA expan-
sion and rupture, albeit these were relatively small AAAs.
Patient anxiety regarding no treatment for their AAA com-
monly appeared to increase during their periodic ultra-
sound surveillance, heightening with each US/S visit. It
seemed to us that insignificant back pain, or anything
causing abdominal pain or discomfort, seemed capable of
triggering patients’ concerns and prompted calls to the
principle investigator’s or study coordinator’s offices be-
tween scheduled US/S visits. Visits to the emergency de-
partment or their primary physician’s office were frequently
interspersed between these calls. One patient called almost
weekly seeking reinforcement regarding the safety of con-
tinued observation without treatment for his AAA. These
calls usually related “new information” the patient had
obtained on the Internet or from friends or relatives ques-
tioning the lack of treatment for an AAA that is known to
be dangerous if not treated. The well-meaning concerns of
family or friends regarding the risk of AAA rupture often
magnified the patient’s anxiety. The frequency of patient
calls and office visits outside those scheduled, exerts con-
siderable pressure on the private investigator and study
coordinating staff. The alternative of dismissing repeated
calls about apparently insignificant “symptoms” pose a
potential litigation risk should the patient’s AAA rupture
while under observation. The ultimate outcome was often a
demand to cross over to AAA repair. The national media
coverage leading up to the passage of the Screening Ab-
dominal Aortic Aneurysms Very Efficiently (SAAAVE) Act,
with its discussions of the risks of AAA rupture, may have
fueled patient concerns even though a main thrust of this
Act is to use US/S to detect and follow smaller AAAs.1
Other AAA RCTs of similar design. An analysis of
three other RCTs focused on the management of AAAs is
included here to demonstrate the effect of patient crossover
from observation to treatment in AAA trials and its impact
on trial outcomes and conclusions based on intent-to-treat
analysis. High crossover rates were encountered in both the
United Kingdom Small Aneurysm Trial 2-4 and Aneurysm
Detection and Management Veterans Affairs Cooperative
(ADAM) Trial 5.
In the United Kingdom Small Aneurysm Trial,4 1090
patients ages 60 to 76 with aneurysms 4 to 5.5 cm in
diameter were randomized to either open repair (OR) or
US/S. Of the 563 patients randomized to OR, 34 expired
while awaiting repair, including 9 who ruptured their an-
eurysm. Of the 527 patients randomized to surveillance,
327 (62%) crossed over to OR by the end of the 4.6-year
mean follow-up period. Less than 38% of patients in the
observation arm actually completed their randomized as-
signment. The majority crossed over because of aneurysm-
related “symptoms” rather than increase in aneurysm size.
Additionally, 63 patients crossed over because of individualpreference or protocol deviation. At last report,6 only 218
remained in the observational arm of the trial (19% of the
total). Some interpreted the trial as showing it was not a
matter of whether or not to repair such AAAs, but when!
The ADAM trial compared the results of immediate
OR with US/S in 1136 veterans (ages 50-79) with 4 to 5.5
cm in diameter AAAs. In this RCT, 569 were randomized
to OR and 567 to US/S. During the 4.8 years mean
follow-up, 61.6% of those randomized to US/S crossed
over to OR, whereas only 7.3% of those randomized to OR
did not undergo OR. Reasons for crossover included
“symptoms” related to the AAA; aneurysm diameter ex-
ceeding the upper threshold of 5.5 cm; increase in AAA
diameter of more than 1 cm per year; need for intervention
for iliac or thoracic aortic aneurysm or patient request. The
majority of patients crossed over because either their aneu-
rysm became “symptomatic” or patient request. The risk of
aneurysm rupture in all patients in this trial was estimated to
be 0.6% per year. Interestingly, two patients awaiting OR
and 11 patients in the surveillance arm ruptured their AAAs
during the period of the trial.
In the United Kingdom Endovascular Aneurysm Re-
pair Trial II (EVAR-II),7 patients over the age of 60 with an
AAA of greater than or equal to 5.5 cm diameter and who
were judged “unfit” (too high risk) for open surgical repair
were randomized to either EVAR or OBS/NoRx. Of three
hundred thirty-eight patients participating in this study,
166 were randomized to EVAR and 172 to OBS/NoRx. In
this trial, 47 patients (27%) crossed over from the OBS/
NoRx arm to AAA repair. In the EVAR arm, 14 of the
patients (8%) died before receiving EVAR, six from AAA
rupture and eight from other causes, presumably related to
comorbidities in these high-risk patients. Ultimately, 197of
all 338 randomized patients (58%) received some form of
aneurysm repair (150 randomized and surviving to un-
dergo EVAR and 47 crossovers). The AAA repair received
was EVAR in 181 and OR in 16. Only 125 of 172 patients
randomized to OBS/NoRx (73%, but only 37% of the total
in the trial) remained in that arm during the duration of the
trial. The 47 patients who crossed over to EVAR from
OBS/NoRx did so for a variety of reasons, the published
list including aneurysm-related “symptoms”, rapid rate of
expansion, or “patient or physician preference” (Table).
Although full details were not given, only five of the 47
patients, those whose AAAs had increased significantly in
size, had what might be conceded as nonsubjective reasons
to cross over to repair. This significant crossover rate, of
course, was not reflected in the intent-to-treat analysis,
which showed no significant difference in overall mortality
between those assigned to EVAR (45%) and those as-
signed to OBS/NoRx (40%). The published report does
state that a per-protocol analysis was done and showed no
significant difference between these two arms in terms of
all-cause mortality (P .07) and aneurysm-related death
(P .43), but some suspected that these analyses did not take
into account those (8%) who did not receive EVAR as
assigned because they died while awaiting repair. However,
even if these 14 patients are excluded, in addition to includ-
nagem
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16 patients receiving OR, not EVAR, the mortality of those
actually receiving EVAR (71/181 39%) is still not statisti-
cally significant compared with those remaining under ob-
servation (57/125 46%) (P  .29). Parenthetically, 21 of
the latter patients died from AAA rupture. This trial is an
example of one in which the apparent effect of crossovers
undermined its acceptance. The differences in mortality
rate percentages being so suggestive. Even though per-
protocol analyses did not significantly favor EVAR, a lack of
acceptance was also likely fueled by differences in outcome
between crossovers and those assigned to receive EVAR.
The 2% initial and 23% late mortality rates for those who
crossed over and received EVAR compared with the 9%
initial and 40% late mortality of those originally assigned to
EVAR were statistically significantly different (initial P 
.005, late P .0008).7,8 Cronenwett, in an invited critique
of these trials for Lancet commented to the effect that the
EVAR II trial proved that patient/physician choice is supe-
rior to randomization.9 The latter differences also became
the focus of subsequent US reports showing much lower
procedural mortalities for EVAR in high-risk cohorts from
the Lifeline registry (2.9%)10 and NISQIP data from the
Veterans Administration (3.1%).11 These seemed more
commensurate with the 2% mortality of crossovers than the
9% mortality of those assigned to EVAR. These publica-
tions indicated that US investigators, some performers of
EVAR, were unwilling to accept the results and conclusions
of this “flawed trial”, in spite of the crossovers making a
statistically significant difference in mortality in a per-pro-
tocol analysis.
DISCUSSION
Patients with a vascular disorder are generally willing to
participate in an RCT addressing its management for altru-
istic reasons in that the information derived from the trial
may help others even if not themselves. Most trials are
based on equipoise and the fact that the patient may have
been made aware when two or more treatment modalities
are being compared it is understood that no one therapy
has been established as “the best of those being compared.”
Table. Analysis of number of patients crossing-over to tre
clinical trials cited
Study
ADAM
n  1136
Treatment arm 569
OBS/NoRx 567
No. of crossover to repair 349
Reasons for crossover:
AAA size 10
AAA diameter increase 0
Patient request or off protocol 31
“Symptomatic” or increasing anxiety 297
AAA, Abdominal aortic aneurysm; ADAM, Aneurysm Detection and Ma
OBS/NoRx, offering observation or no treatment.Where some form of therapy is being offered to thoseenrolled in all arms of the trial, the patient may accept
randomization as long as no bias regarding which treat-
ment is superior exists. In contrast, those RCTs dealing
with a perceived life-threatening condition (ie, AAA) and,
which offer an OBS/NoRX arm present difficulties in
patients’ accepting randomized assignment to OBS/NoRx
and staying with it.
Many patients being evaluated for AAA already possess
some information regarding the indications for AAA repair,
the different procedural options involved and have some
appreciation for both the risks and benefits associated with
these options. Patient bias was encountered in many, if not
most, of the trials for FDA approval of the various aortic
stent grafts. Although it was originally intended that EVAR
be randomly compared with OR, randomization to OR was
often not accepted by patients who really “sought” EVAR,
possibly aware of the “hype” associated with the stent grafts
that emphasized EVAR’s potential of lower morbidity and
faster return to normal activities. Because of patient bias,
ultimately the “controls” in these FDA trials had to be
made up of those with unsuitable anatomy for endovascular
repair. Indeed, it is not uncommon today for AAA patients
to present themselves not only expecting EVAR but even
identifying the particular stent graft they have heard has the
best treatment record. Various forms of “hearsay”, includ-
ing Internet sites accessed by the patient or their family or
friends, or anecdotal comments by friends or family, all play
a role in producing this crossover phenomenon.
When initially screened, patients with little previous
information may readily accept randomization to an OBS/
NoRx arm because of the perception that observation
without treatment carries an extremely low risk for adverse
outcome. However, as these patients continue to partici-
pate in the trial, they naturally investigate their condition
further and, if they obtain “information” from family or
friends or the Internet, which leads them to believe their
condition is potentially life-threatening if untreated, they
become increasingly concerned of the advisability of con-
tinuing in an OBS/NoRx arm. The end result often is that
rather than openly challenge information regarding risk
received from the private investigator or study coordina-
nt from observation/no treatment in the randomized
EVAR-II
n 338
UK small AAA
n 1090
Our experience
n  37
166 563 18
172 527 19
47 327 10
0 0 0
5 0 2
14 63 2
26 247 6
ent Veterans Affairs Cooperative; EVAR, endovascular aneurysm repair;atmetors, they may dwell on or magnify “symptoms”, which
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Repeated calls and other expressions of these growing
concerns exert increasing pressure on the investigator or
trial coordinating staff who is obliged to approve their
eventual request to cross over to treatment.
Many patients, or those close to them, perceive, or
come to perceive, an AAA as a “ticking time bomb” and
wish to be relieved of its threat. This may be reflected in the
subsequent improvement beyond an initial period of 3 to 6
months in quality of life observed in those undergoing AAA
repair vs those who did not.12,13 The observation group of
an AAA trial are reminded of the potential rupture risk
every time they are required to return for US/S. This may
be likened to a “Sword of Damocles effect”, ie, a perceived
risk, the removal of which brings relief. Despite medical
knowledge of the relationship of AAA size to rupture risk
and its use as positive reinforcement by healthcare profes-
sionals participating in small AAA trials, the patient’s per-
ception of the risk for AAA rupture ultimately will prevail,
and since most clinical trials with OBS/NoRx arms appro-
priately offer the opportunity for crossover to treatment
related to changes in clinical status or patient desire, this
option ends up being taken by a substantial portion of the
patients over time with a significant impact on the outcome
of the trial or the acceptance of conclusions drawn there-
from.
The end point of most AAA RCTs is mortality, but it
can be argued that the primary objective when treating
patients with AAAs is not to prolong life, for many have
significant life-threatening comorbidities, but to prevent
AAA rupture or, at least, death from that event. Although
the three cited trials failed to show an overall mortality
advantage for treatment, their data appear to support the
conclusion that both OR and EVAR prevent AAA rupture.
In the EVAR-II Trial, only one of 213 patients (0.5%)
whose AAA was repaired had AAA rupture, while 8 AAA
ruptures occurred in the 125 surveillance patients (6.4%).
This represents a significant difference (P  .002 using
Fisher exact test). In the UK Small Aneurysm Study, three
of 890 repaired patients (0.03%) had AAA rupture, while
26 ruptures (17 under surveillance plus 9 waiting repair)
occurred in 125 patients not receiving a repair (20.8%).
This also represents a significant difference (P .0001
using Fisher exact test). US/S of patients with AAAs in
itself obviously offers no protection from rupture, although
it may detect “too-rapid” growth or growth reaching an
accepted interventional threshold diameter and thus dictate
the need for repair. However, compliance with US/S sur-
veillance of AAAs may be better in some (eg, European)
countries than in North America14 and, in fact, it has shown
to be poor in one US study, even when surveillance is free.
Valentine reported 32% noncompliance in a United States
small aneurysm surveillance trial with 27% failing to keep
any scheduled appointments and 5% lost after one to two
follow-up visits. Four of these noncompliant patients had
documented AAA rupture.15
We believe our concerns about AAA trials of this design
are appropriate. The question remains, is there a solution tothis dilemma? Some of the following might be considered
in future AAA trials at least: (1) Randomization in RCTs of
this design might be weighted more heavily toward the
OBS/NoRx arm (ie, 2:1), to compensate for inevitable
high crossover rate, especially if intent-to-treat analysis is
the primary method used. (2) Drop subjects who cross over
in either direction. While this has the benefit of maintaining
the randomized trial, it could be argued that the sample is
now biased if significantly more subjects cross over from the
NoRx to Rx arms. (3) Per-protocol analysis should always
be reported, in addition, comparing those actually receiv-
ing treatment versus those remaining in the OBS/NoRx
arm. (4) RCTs of this design should not be conducted in
health care systems in which waiting times for elective
admission are characteristically long and the time between
randomization and receiving the assigned treatment cannot
be shortened for trial enrollees (eg, a mean of 57 days for
AAAs of mean diameter of 6.7 cm in the EVAR I trial). (5)
Trials of this design should be restricted to small AAAs (ie,
those where the risk of rupture under surveillance is accept-
ably low (ie,1%-3%/year). (6) Should treatment with any
agent currently undergoing trial (eg, roxithromycin, doxy-
cycline, statins, angiotensin-converting enzyme inhibitors,
beta receptor blockers, or protease inhibitors) be shown to
reduce AAA growth, they could be included in the surveil-
lance arms of AAA trials in the future, as best medical
therapy and thus help to reduce the crossover rate.16 (7)
Although both all-cause mortality and AAA-related death
should continue to be reported (the latter along with the
autopsy rate for deaths occurring in the period beyond 30
days), AAA rupture should also be at least a secondary end
point for such RCTs. Without such changes, conclusions
derived from AAA trials with OBS/NoRx arms are likely to
have unacceptably high crossover rate and their results and
conclusions are unlikely to gain acceptance, even though
they are considered to constitute level I medical evidence.
It may well be that certain vascular diseases, which have
a perceived life-threatening outcome, should not be evalu-
ated using RCTs containing an OBS/NoRx arm. Human
nature coupled with the patient’s desire for survival predis-
poses the patient to want therapy for a perceived life-
threatening condition.
CONCLUSIONS
Based on an experience in a current AAA RCT and our
analysis of other AAA RCTs that offer OBS/NoRx arms,
we conclude that this trial design fails to take human nature
into account and results in significant crossover rates to the
treatment arm in AAA trials. This can obfuscate the com-
parison of management options using intent-to-treat anal-
ysis. RCTs of this design or their conclusions have usually
led to significant controversy, in large part, related to the
numbers of subjects who cross over to the treatment arm.
Nevertheless, their potential impact on clinical decision
making and reimbursement can be quite significant. This
inherent weakness has commonly resulted in these trials not
resolving to the satisfaction of many, if not most, clinicians
the issue at which they were directed. We have offered some
JOURNAL OF VASCULAR SURGERY
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to the test in mitigating this dilemma, may at least offer
additional helpful perspective in viewing the outcomes of
these trials.
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